Tonmya FDA — First Fibromyalgia Drug in 15 Years. 10M US Patients 80% Women Blind Spot Released
Fibromyalgia 10M US patients·80% women·chronic widespread pain·fatigue·sleep·cognitive. But 15 years no new drug. Tonix Pharmaceuticals 2025.11 FDA approval — Tonmya (cyclobenzaprine sublingual) = first fibromyalgia drug in 15 years. Women’s chronic pain policy gap first resolution.
Key Announcement
Tonmya FDA: Approval 2025.11, fibromyalgia indication, cyclobenzaprine sublingual, bedtime once, non-opioid
RELIEF / RESILIENT Phase 3: n=1,474, 14 weeks, pain reduction -1.9 vs placebo -1.5 (p=0.01), good safety, sleep·cognitive improvement
Fibromyalgia - Women’s Blind Spot
Prevalence: US 10M, 80% women, Korea 23M estimated, 20~60 years common
Symptoms: Chronic widespread pain (3+ months), tender points (18), chronic fatigue, sleep disorder (delta sleep deficit), cognitive (fibro fog), depression·anxiety
Cause (presumed): Central pain processing abnormal, autonomic imbalance, hormonal fluctuation, post-trauma·stress onset
15-Year Policy Gap
Existing fibromyalgia drugs (FDA): Lyrica (pregabalin) 2007, Cymbalta (duloxetine) 2008, Savella (milnacipran) 2009, then 15 years drug absence
Why policy gap: Fibromyalgia = diagnosis difficult (no objective markers), patient complaint-dependent, clinician skepticism common (“psychological”), clinical trial challenges, women-predominant → low priority
Tonmya Mechanism
Cyclobenzaprine: Skeletal muscle relaxant (traditional), central action (brainstem·spinal cord), serotonin·norepinephrine impact, sleep + pain simultaneous
Sublingual new formulation: Fast absorption, hepatic first-pass avoidance (↑ effect), bedtime once = convenience
Fibromyalgia action: Central pain processing normalization, sleep improvement → recovery, ↓ cognitive impairment
L74 Dimension - 3rd Axis
40 pillars + chronic pain new area: L74 VYEPTI (migraine cognitive) + L74 Tonmya (fibromyalgia 15-year policy) = women’s chronic pain L63~L73 absent area, L74 2-axis entry.
Women’s Fibromyalgia - Hormonal·Pregnancy·Menopause
Hormone: Estrogen → pain processing impact, premenstrual worsening (PMDD overlap), pregnancy partial improvement·worsening, perimenopausal worsening
Women comorbidities: Depression (50%+), anxiety (30%+), IBS (40%+), migraine (50%+, L74 VYEPTI overlap), ME/CFS, RA (10%)
Korean Implications
Korean fibromyalgia: Diagnosis difficult (specialist shortage), Lyrica·Cymbalta insurance, medical shopping common, ↓ clinician awareness
Tonmya adoption: FDA → Korean MFDS 1~2 yr, 2027 expected, $200~$500/month, insurance negotiation
Daily Guide
Diagnosis: Rheumatology·pain clinic, tender point exam·symptom eval, ACR 2016 criteria, 6~12 month follow-up
Drug stages: 1st Lyrica·Cymbalta·Savella, 2nd antidepressant·painkiller, 3rd Tonmya (post-L74 adoption)
Non-drug (essential): Daily low-intensity exercise, sleep (7~9 hours), stress management, CBT·family support
Hormone: Perimenopausal HRT consult, premenstrual prophylaxis
FAQ
Q. Fibromyalgia real disease? A. Objective markers absent so skepticism common. But ACR·FDA·international criteria clear. Hormonal·central·autonomic multi-axis.
Q. Tonmya better than existing? A. Phase 3 vs placebo significant (p=0.01). Patient variability. Doctor decision.
Q. Cyclobenzaprine = muscle relaxant? A. Existing indication muscle spasms. Tonmya = sublingual·bedtime·fibromyalgia new indication.
Q. Non-opioid = no dependence risk? A. No opioid dependence risk. But drowsiness·dry mouth possible. Clinician monitoring.
Q. Korea availability? A. Post-FDA Korean MFDS 1~2 yr. 2027 expected. Meanwhile Lyrica·Cymbalta·Savella·antidepressants.
Conclusion
Tonmya FDA = first fibromyalgia drug in 15 years. US 10M·80% women. L74 = 55 pillars + expansion·global·policy dimension (chronic pain policy gap 3rd axis). Korea 2027. Women’s chronic pain policy gap first resolution.